USP9X and leukemia: Although direct ERG targeting poses challenges due to its essential role in hematopoietic stem cells, combinatorial approaches can establish a leukemia-specific therapeutic window, and emerging approaches such as small-molecule degraders and disruption of ERG-stabilizing partners including USP9X may allow selective inhibition of aberrant ERG activity in leukemia.